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Abstract
Background Sorafenib is recommended for the treatment of
advanced-stage hepatocellular carcinoma (HCC).
Nonetheless, it is expensive, effective in few patients, and
may cause significant adverse effects. Therefore, accurate se-
lection of patients is needed. In a previous study, we construct-
ed a simple scoring system to predict patients’ outcomes based
on the occurrence of sorafenib adverse effects.
Objective The present study aimed to validate this scoring
system in a real-life cohort of HCC patients.
Patients and Methods Clinical records of 279 outpatients
treated with sorafenib in eight Italian centers were
retrospectively analyzed. Adverse effects considered to calcu-
late the score were skin toxicity, diarrhea, and arterial hyper-
tension, occurring during the first month of therapy. For each
adverse effect, 1 point was assigned if present; and 0 points if
absent (resulting in a total score between 0 and 3).
Results Median overall survival (OS) was 10.8 months and me-
dian time to progression (TTP) was 5.1 months. At multivariate
analysis, performance status, α-fetoprotein (AFP), and Child-
Pugh score were independently associated with TTP and OS.
A progressive increase of OS and TTP was observed in patients
with scores from 0 to 3 (p < 0.001). Six-, 12-, and 24-month
survival probabilities were 55.1, 24.5, and 7.9% in score 0 pa-
tients, and 100, 80.9, and 46.2% in score 3 patients, respectively.
Complete response was observed in one patient (0.4%), partial
responses in 41 (15.2%), and stable disease in 117 (43.5%). The
disease control rate in patients with scores of 0, 1, 2, and 3 was
34.3, 51.6, 80.9, and 96.3%, respectively (p < 0.001). Complete
or partial responses were not observed in score 0 patients.
Conclusions Wehave validated a useful scoring system to predict
outcomes in sorafenib-treated HCC patients. This score is easy to
calculate and suitable for implementation in daily clinical practice.
Key Points
Sorafenib is recommended for the treatment of advanced
hepatocellular carcinoma; neverthless it is difficult to
manage.
Our score, based on the early occurrence of adverse
effects, is able to predict the clinical outcomes of the
therapy.
In our cohort, patients with higher scores had better 
chances of overall survival.
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1 Introduction
Hepatocellular carcinoma (HCC) is one of the deadliest can-
cers. Although it represents only approximately 4% of all new
cancer cases diagnosed worldwide, HCC is the fourth leading
cause of cancer death in males and the sixth in females [1].
Most cases develop in the setting of chronic liver inflamma-
tion that has progressed to cirrhosis, the main risk factor in 70–
90% of patients. About 80% of cases occur in patients infected
with hepatitis B virus (HBV) or hepatitis C virus (HCV) [2].
In recent years, a net increase in cases related to other risk
factors has been noted, with non-alcoholic steato-hepatitis
(NASH) as a predominant factor [3].
Knowledge of the risk factors for HCC provides an oppor-
tunity for the development and implementation of preventative
strategies aiming to decrease the worldwide burden of the dis-
ease [4]. For this purpose, national and international associa-
tions have issued guidelines on surveillance strategies for early
diagnosis of HCC, based on the use of periodic ultrasound
examinations [5–7]. However, despite the increasing use of
surveillance and technical advances in ultrasound imaging,
HCC is diagnosed at an early curative stage in only a third of
western patients [6]. In the majority of cases, the diagnosis is
made when HCC is multifocal or in an advanced stage.
In advanced-stage HCC and in selected cases of multifocal
tumors, the small-molecule tyrosine kinase inhibitor sorafenib
(Nexavar®, Bayer Health Care, Leverkusen, Germany) is rec-
ommended for first-line treatment [5–7]. It decreases tumor cell
proliferation and angiogenesis, and increases the rate of apopto-
sis in a wide range of experimental tumors [8, 9]. Sorafenib acts
by inhibiting the kinase activity of Raf-1 and B-Raf, the vascu-
lar endothelial growth factor (VEGF) receptor (VEGFR) family
1, 2, and 3, and platelet-derived growth factor receptor β
(PDGFR-β) [10]. It is currently the only approved drug for
the first-line treatment of advanced HCC, having demonstrated
survival benefits in two randomized phase III studies: the
SHARP (Sorafenib HCC Assessment Randomized Protocol)
[11] and Asia-Pacific [12] trials. The efficacy of sorafenib has
been confirmed in clinical practice in several studies, including
the large international GIDEON (Global Investigation of ther-
apeutic DEcisions in HCC and Of its treatment with sorafeNib)
trial [13]. However, this drug is expensive, effective only in a
proportion of patients, and may cause adverse effects that cause
the patients’ quality of life to deteriorate.
The correct selection of patients who are likely to benefit
from treatment is the main goal of personalized medicine, and
is needed in the case of sorafenib in order to save costs and
optimize results. Several studies exploring baseline character-
istics of treated patients have failed to identify useful markers
for the prediction of sorafenib efficacy and patient survival
[14–18]. Even pre-treatment evaluation of plasma biomarkers
failed to predict the efficacy of therapy [19, 20].
Consequently, the use of pre-treatment biochemical and
clinical parameters or their combination to predict the out-
comes of sorafenib therapy remains an issue.
Based on reported data in the literature regarding HCC and
other neoplasms treated with angiogenic inhibitors, we tried to
find a correlation between ‘anti-angiogenic’ adverse events
and overall survival (OS) [21, 22]. In a previous study, we
constructed a simple scoring system based on the occurrence
of some sorafenib on-target effects in off-target tissues (OTE)
that may be used in clinical practice to guide treatment [23].
The resulting OTE score was able to predict patient outcomes
at 4 weeks of sorafenib therapy. The aim of the present study
was to validate this score in an independent cohort of HCC
patients treated with sorafenib in field practice.
2 Methods
2.1 Patients
Clinical records of 279 outpatients treated in eight Italian can-
cer centers between September 2008 and September 2015
were retrospectively analyzed. This population is independent
from patients in two liver units that were previously evaluated
to construct our score [23]. Diagnosis of HCC was made ac-
cording to European Association for the Study of the Liver
(EASL) practice guidelines [5]. Patients were assigned to so-
rafenib therapy when surgical or locoregional treatments
failed or were not applicable due to cancer diffusion and liver
failure. Informed consent was obtained from each patient be-
fore starting sorafenib and the study design was approved by
the local ethical committees and the ethics committee of
Cardarelli Hospital.
2.2 Score Calculation
Toxicities were evaluated according to the Common
Terminology Criteria for Adverse Events (CTCAE; version
4.0). To calculate the total score, the occurrence of three so-
rafenib OTE within the first 4 weeks of therapy was recorded:
skin toxicity, diarrhea, and arterial hypertension. Skin toxicity
was defined as the occurrence of hand–foot skin reaction
(HFSR) and rash alone or in combination. In order to simplify
the calculation of the score and to avoid possible bias, each
adverse event was either assigned 0 points if absent or 1 point
if present. Therefore, the total score ranged between 0 and 3.
Due to incomplete or missing data, the score could be calcu-
lated for 265 of 279 (95%) patients.
2.3 Outcomes and Assessments
The primary outcome was OS, defined as the time from
starting treatment to death or last contact. Secondary outcomes
were time to progression (TTP) and the disease control rate
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(DCR) at imaging according tomodified Response Evaluation
Criteria in Solid Tumors (mRECIST) for HCC [24]. TTP was
defined as the time between starting treatment and first evi-
dence of radiological progression. Deaths occurring during
follow-up without evidence of radiological progression were
censored. DCR was defined as the percentage of patients
whose best response at imaging was complete response, par-
tial response, or stable disease.
2.4 Statistical Analysis
Continuous variables are shown as mean, median, and 95%
confidence intervals (CIs). Categorical variables are presented
as numbers and percentages. Patient survival was analyzed
using Kaplan–Meier curves and differences between survival
rates were compared using the log-rank test. A two-tailed p-
value <0.05 was considered statistically significant. For uni-
variate analysis, the following baseline factors were consid-
ered and analyzed as categorical covariates: age, gender,
Eastern Cooperative Oncology Group(ECOG) performance
status (PS), hepatitis B and C infection, α-fetoprotein (AFP)
level, Barcelona Clinic Liver Cancer (BCLC) stage,
macrovascular invasion, extrahepatic spread, Child-Pugh,
and Model for End-Stage Liver Disease (MELD) score. All
variables with a p-value <0.10 in the univariate analysis were
included in a backward stepwise Cox’s proportional hazard
model. To evaluate whether the predictive value of the score
was influenced by covariates, the Pearson chi-square test was
used to evaluate the distribution of factors independently re-
lated to OS and TTP among different score classes. Finally, to
test the discriminatory ability of the scoring system, receiver
operating characteristic (ROC) curves were generated and the
areas under the curve were assessed. Analyses were per-
formed with software package SPSS® for Mac (Rel SPSS
21.0; IBM Corporation, Armonk, NY, USA).
3 Results
3.1 Patient Characteristics
Main baseline patient characteristics are shown in Table 1.The
median age of the 279 patients was 69 (range 28–88) years.
Most patients were males, with Child-Pugh A viral cirrhosis,
ECOG PS 0, and BCLC stage C HCC. In 75% of patients,
sorafenib treatment was started with a full dose of 400 mg
twice daily; in the remaining 25%, the starting dose was re-
duced to 400 mg daily according to the physician’s judgment.
Median treatment duration was 3.5 (range 0.2–48.6) months.
During the study period, 253 patients died and the median
OS was 10.8 (95% CI 9.0–12.6) months (Fig. 1a). Cancer
progression was observed in 271 patients, and the median
TTP was 5.1 (95% CI 4.4–5.7) months.
In an univariate analysis, baseline variables ECOG PS 1
and Child-Pugh score 6 were significantly associated with
shorter TTP; hepatitis B infection, ECOG PS 1, and AFP
>400 ng/mL were significantly associated with poorer OS
(Table 2).
3.2 Validation of the Scoring System
At 1month of therapy, 230 of 279 (85.7%) patients experienced
one or more OTE. Skin toxicity was observed in 126 of 279
(45.2%) patients, including grade 3 in 14 patients. Median OS
was 14.4 (95%CI 12.0–16.8) and 5.8 (95%CI 4.6–7.1) months
in patients with and without skin toxicity (p = 0.005), and
Table 1 Demographic and clinical characteristics of patients (n = 279)
at baseline
n (%)a
Males 237 (84.9)
Median age [years (range)] 69 (28–88)
Cirrhosis 269 (96.4)
HCV 162 (58.1)
HBV 38 (13.7)
Alcohol 31 (11.1)
NAFLD 27 (9.7)
BCLC
B 77 (27.6)
C 202 (72.4)
Portal thrombosis 93 (33.3)
Extrahepatic metastasis 125 (44.8)
Child-Pugh score
5 171 (61.3)
6 91 (32.6)
7 14 (5.0)
8 3 (1.1)
MELD score [median (range)]
(missing in 3 patients)
8 (6–16)
ECOG 0/1/2 166 (59.5)/101
(36.2)/12 (4.3)
Prior therapy
None 130 (46.6)
Resection 57 (20.4)
Locoregional 50 (17.9)
Missing data 42 (15.1)
α-fetoprotein ng/mL [median (range)]
(missing in 12 patients)
38.5 (1–50,000)
α-fetoprotein >400 ng/mL
(missing in 19 patients)
182 (70.0)
Median follow-up [months (range)] 9.4 (0.5–71.8)
a Unless otherwise stated
BCLC Barcelona Clinic Liver Cancer, ECOG Eastern Cooperative
Oncology Group, HBV hepatitis B virus, HCV hepatitis C virus,
MELD Model for End-Stage Liver Disease, NAFLD non-alcoholic fatty
liver disease
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median TTP was 8.8 (95% CI 7.6–10.0) and 3.9 (95% CI 3.0–
4.8) months (p = 0.001) in these patients (Fig. 1b). Grade 1 or 2
arterial hypertension occurred in 121 of 265 (45.7%) patients.
Median OS and TTP were 15.1 (95% CI 12.9–17.3) and 7.6
(95% CI 6.0–9.2) months in patients with arterial hypertension,
and 7.5 (95% CI 5.9–9.2) and 3.7 (95% CI 3.1–4.2) months in
patients without hypertension (both p < 0.001), respectively
(Fig. 1c). Diarrhea was observed in 75 of 279 (26.9%) patients
and it was grade 3 in ten (13.3%) patients. Median OS and TTP
were 15.6 (95% CI 11.1–20.1) and 7.3 (95% CI 5.5–9.1)
months in patients with diarrhea, and 9.2 (95% CI 7.6–10.8)
and 4.1 (95% CI 3.5–4.8) months in patients without diarrhea
(both p < 0.001), respectively (Fig. 1d).
The occurrence of OTE was comparable between patients
treated with full-dose and reduced-dose sorafenib. Skin toxic-
ity was observed in 51.3 and 42.1%, hypertension in 46.3 and
51.5%, and diarrhea in 23.9 and 21.1% of patients treated with
full and reduced dose sorafenib, respectively.
A progressive increase in median OS and TTP was ob-
served in patients with score 0–3 (p < 0.001) (Table 3, Fig.
2). The survival probabilities at 6, 12, and 24 months were
55.1, 24.5, and 7.9% in patients with score 0; 62.8, 40.4, and
19.6% in patients with score 1; 85.6, 59.0, and 22.8% in pa-
tients with score 2; and 100, 80.9, and 46.2% in patients with
score 3, respectively.
A landmark analysis, excluding patients with less than
4 weeks of treatment and follow-up, confirmed the predictive
value of the score with median OS of 7.9, 9.2, 15.1, and
23.9 months in patients with score 0, 1, 2, and 3, respectively
(p < 0.001).
Radiologic response was evaluated in 269 patients with a
follow-up of at least of 2 months. Of these, 110 (40.9%) patients
progressed.One complete responsewas observed (0.4%), partial
responses were observed in 41 (15.2%) patients, and stable dis-
ease in 117 (43.5%) patients. Therefore, the overall DCR was
59.1%. DCR in patients with score 0, 1, 2, and 3 was 34.3, 51.6,
Fig. 1 Overall survival in the entire study population and according to
off-target event occurring within the first 4 weeks of treatment: (a) in the
entire study population; (b) in patients with and without skin toxicity; (c)
in patients with and without arterial hypertension; and (d) in patients with
and without diarrhea. Tox toxicity
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80.9, and 96.3%, respectively (p < 0.001). Complete or partial
responses were not observed in patients with score 0, but oc-
curred in 12.1% of patients with score 1, 23.5% of patients with
score 2, and 44.4% of patients with score 3 (p < 0.001).
To evaluate the discriminatory ability of our scoring sys-
tem, ROC curves for survival status at different timepoints
were constructed. The area under the ROC curves at 6, 12,
and 18 months of follow-up were 0.694 (95% CI 0.629–
0.759), 0.687 (95% CI 0.621–0.752), and 0.715 (95% CI
0.645–0.785), respectively (Fig. 3).
Multivariate analysis showed that PS, Child-Pugh score,
and AFP were independently associated with TTP and OS
(Table 4). These variables were equally distributed among
different classes of OTE score (Table 5).
Table 2 Pre-treatment clinical
variables for predicting time to
progression and overall survival:
univariate Cox proportional
hazard ratios, 95% confidence
intervals, and p-values
Time to progression Overall survival
Median time
(months)
95% CI p-Value Median time
(months)
95% CI p -Value
Gender
Male 5.1 4.2–5.9 0.796 10.4 8.5–12.2 0.488
female 5.2 3.4–7.0 11.8 9.3–14.2
Age (years)
>69 5.1 4.0–6.1 0.830 11.2 7.5–14.9 0.326
≤69 4.8 4.2–5.5 10.6 8.4–12.7
Etiology
Viral 5.2 4.4–5.9 0.894 11.1 8.8–13.5 0.552
Non-viral 4.8 4.1–5.5 9.7 6.7–12.6
Hepatitis B
Present 5.1 4.0–6.1 0.968 6.8 3.9–9.7 0.039
Absent 5.1 4.3–5.8 11.8 9.7–13.8
Hepatitis C
Present 5.3 4.3–6.2 0.883 12.8 10.2–15.3 0.066
Absent 4.9 4.3–5.6 8.8 7.3–10.3
BCLC
C 4.6 3.7–5.5 0.129 9.7 8.1–11.3 0.397
B 6.2 4.8–7.6 13.2 9.9–16.4
ECOG
1–2 3.8 2.8–4.8 0.001 8.0 6.5–9.5 0.000
0 5.6 4.6–6.6 14.3 12.3–16.3
Child-Pugh score
≥6 3.0 2.5–3.4 0.009 9.7 7.9–11.4 0.062
5 4.0 3.3–4.7 11.3 9.1–13.4
MELD score
>8 4.5 3.7–5.3 0.274 8.8 7.6–10.0 0.123
≤8 5.6 4.6–6.6 12.8 10.5–15.0
AFP (ng/mL)
>400 4.5 3.3–5.7 0.086 9.2 5.9–12.6 0.010
≤400 5.3 4.4–6.2 11.8 9.4–14.3
Portal thrombosis
Yes 4.0 2.1–5.9 0.746 9.1 6.5–11.8 0.698
No 5.2 4.5–5.9 11.1 9.6–12.7
Extra-hepatic metastasis
Yes 4.9 4.2–5.6 0.737 10.5 8.2–12.8 0.948
No 5.2 2.8–4.6 11.1 8.4–13.9
AFP α-fetoprotein, BCLC Barcelona Clinic Liver Cancer, CI confidence interval, ECOG Eastern Cooperative
Oncology Group, MELD Model for End-Stage Liver Disease
Table 3 Median overall survival and time to progression according to value of the score
OTE score Occurrence rate (%) ( n = 265) TTP [months (95% CI)] OS [months (95% CI)]
0 28.3 2.4 (1.9–2.8) 7.0 (5.1–9.0)
1 35.1 2.8 (2.0–3.5) 8.8 (5.8–11.9)
2 26.4 5.4 (4.7–6.0) 15.1 (12.5–17.6)
3 10.2 10.6 (7.0–14.3) 23.9 (19.7–28.1)
CI confidence interval, OS overall survival, OTE on-target effects in off-target tissues, TTP time to progression
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4 Discussion
In the present study, we validated a simple score to predict the
outcomes of HCC patients treated with sorafenib. This score
can be calculated after 4 weeks of treatment and may be a
useful tool for guiding physicians’ choices.
In HCC patients, especially when the cancer is in an ad-
vanced stage, the prediction of prognosis is very complex
because survival is affected by both tumor burden and the
impairment of liver function due to the underlying cirrhosis.
When HCC patients are treated with sorafenib, this is even
more challenging because the drug increases survival and dis-
ease control only in a proportion of cases.
Several studies have investigated demographic, biochemi-
cal, and imaging characteristics of HCC patients prior to
starting sorafenib—with the goal of identifying which patients
have the highest benefit from therapy. Unfortunately, despite
all of these efforts, there are no pre-treatment variables that
can be reliably used to select patients with the highest chance
of benefit from sorafenib therapy. Subgroup analyses of the
SHARP trial showed that sorafenib improved survival and
DCR irrespective of baseline characteristics, including etiolo-
gy, PS, tumor burden, and previous treatments [11]. Similar
results were observed in the subgroup analyses of the Asian-
Pacific trial; in which baseline evaluation of AST, ALT, bili-
rubin, and AFP concentrations also did not affect sorafenib
efficacy [14]. Meta-analyses of published studies to identify
baseline characteristics that may affect the efficacy and safety
of sorafenib have shown conflicting results [25–28]. For the
same purpose, pre-treatment plasma biomarkers have been
evaluated. The largest study performed on patients enrolled
in the seminal SHARP trial showed that lower plasma levels
Fig. 3 Receiver operating characteristic curves for survival status at 6
(a), 12 (b), and 18 (c) months of therapy
Fig. 2 Overall survival according to the on-target effects in off-target
tissues score
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of VEGFAwere independently associated with better OS both
in treated and in untreated patients, but no correlation with
sorafenib efficacy was found [19]. A recent meta-analysis also
suggested a correlation of VEGF with progression-free sur-
vival, but this finding needs to be confirmed in well-designed
studies [10]. In the phase III SEARCH (Sorafenib and
Erlotinib, a Randomized Trial Protocol for the Treatment of
Patients With Hepatocellular Carcinoma) trial, higher baseline
plasma VEGFC correlated with longer TTP and better DCR
[29]. Therefore, reliable plasma biomarkers for the prediction
of sorafenib treatment effects are yet to be identified. Takeda
et al. proposed the Japan Red Cross (JRC) score to predict the
prognosis of sorafenib therapy and classified three groups:
low, intermediate, or high risk. This score was based on base-
line characteristics of patients [30].
In our cohort, ECOG PS 1, AFP >400 ng/mL, and Child-
Pugh score were associated with poorer TTP and OS. All of
these variables are subject to some degree of bias due to the
presence of major tumor burden, end-stage liver disease, and
more aggressive cancer.
More promising results seem to come from the evaluation
of on-treatment variables, such as AFP response or occurrence
of adverse events. AFP response is defined as a >20% de-
crease from baseline serum AFP within the first 2–8 weeks
of treatment. AFP has the advantage that it is a simple,
objective, and inexpensive test. The main limitation is that
AFP response can only be evaluated in patients with increased
baseline values of this marker. In this series, only 56% of
patients had a baseline AFP value >20 ng/mL.
In the majority of published series, HCC patients treated
with a reduced dose of sorafenib—due to the occurrence of
OTE—have better outcomes than patients receiving the full
dose of the drug [11–13, 15, 18]. OTE are the consequence of
on-target sorafenib effects in off-target tissues and are dose-
related; therefore, their occurrence and grade to some extent
reflect the intensity of the drug effect. Among OTE, skin tox-
icities, mainly HFSR and rash, have been investigated the most.
HFSR is the most common and dose-limiting toxicity of soraf-
enib [31, 32]. Several published studies in patients with ad-
vanced HCC have shown a stable relationship between the
occurrence of this adverse event and TTP or OS [21, 33–35].
All these studies have been retrospective and with relatively
small populations, but show similar results of better prognosis
in patients who develop HFSR. A study by Reig and colleagues
prospectively evaluated the outcomes of early dermatological
effects in 147 HCC patients treated with sorafenib, reporting
that the development of dermatologic adverse events within
60 days of sorafenib initiation was associated with better sur-
vival [36]. In our study, skin toxicity occurred in about 45% of
patients and was severe in less than 10% of these cases.
Table 4 Multivariate analysis of
prognostic factors for predicting
time to progression and overall
survival
Variable Time to progression p-Value
(Cox regression)
Overall survival p-Value
(Cox regression)
Hazard ratio 95% CI Hazard ratio 95% CI
ECOG ≥1
Yes 1 0.003 1 0.000
No 1.48 1.14–1.92 1.81 1.38–2.38
Child-Pugh score
≥6 1 0.040
5 1.32 1.01–1.72
AFP (ng)
≥400 1 0.059
<400 1.32 1.00–1.75
AFP α-fetoprotein, CI confidence interval, ECOG Eastern Cooperative Oncology Group
Table 5 Distribution of variables independently related to time to progression and overall survival among the classes of on-target effects in off-target
tissues score
Score ECOG p-Value Child-Pugh score p-Value AFP p-Value
0 ≥1 5 ≥6 <400 ng ≥400 ng
0 37 (49.3) 38 (50.7) 0.120 39 (52.0) 36 (48.0) 0.226 44 (64.7) 24 (35.3) 0.302
1 62 (66.7) 31 (33.3) 63 (67.7) 30 (32.3) 62 (68.9) 28 (31.1)
2 43 (61.4) 27 (38.6) 43 (61.4) 27 (38.6) 52 (78.8) 14 (21.2)
3 18 (66.7) 9 (33.3) 16 (59.3) 11 (40.7) 17 (65.4) 9 (34.6)
All values are given as n (%)
AFP α-fetoprotein, ECOG Eastern Cooperative Oncology Group
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Arterial hypertension is a common OTE occurring during
therapy with angiogenesis inhibitors. In two meta-analyses,
also including patients with other cancers treated with sorafe-
nib, the overall occurrence of hypertension was 19.1–23.4%
[37, 38]. In our present study, arterial hypertension occurred in
about 45% of patients, a very high incidence that can be due to
sampling variability. However, it should also be considered
that the incidence may be underestimated in clinical trials that
include highly selected patients with health states better than
that observed in field-practice series such as the present one.
The development of sorafenib-related hypertension has been
correlated with treatment efficacy. The data are well corrobo-
rated for other solid tumors [39–42]; but data in HCC patients
are scarce [43, 44].
Gastrointestinal symptoms such as diarrhea, nausea, and
dyspepsia are very common during sorafenib therapy.
Among these symptoms, diarrhea is the most common. In
clinical trials, diarrhea was reported in 25–48% of cases for
all grades and 2–8% for grades 3 and 4, and was also the main
cause of dose reduction in the SHARP trial [45]. Diarrheamay
be due to the blockage of EGFR, which is highly expressed in
intestinal epithelium, and partly to the inflammatory reaction
of the gut to sorafenib [46]. Few studies have reported a sig-
nificant correlation between diarrhea and sorafenib efficacy;
but from available data it seems that the occurrence of diarrhea
is associated with improved OS [47, 48] and longer TTP [49].
In our series, diarrhea occurred in 26.9% of patients and was
mild in most cases.
Our score, constructed using these three OTE confirmed its
ability to discriminate patients with different OS and TTP. The
prediction of these outcomes was comparable with those ob-
served in our previous study in which the scoring system was
constructed [23]. The score is also useful for predicting radio-
logic response: no patients with a score of 0 showed a com-
plete or partial response at imaging evaluation. Combined data
from our current and previous study shows that 161 (29.5%)
of 545 patients had a score 0 and only 4% of these patients
showed a partial response.
To improve the adherence to therapy, it is crucial to explain
to patients that skin toxicity, hypertension, and diarrhea are
predictive factors of better efficacy of sorafenib. Careful and
continuous symptomatic treatment of these events is impor-
tant to ameliorate the patients’ quality of life, improving com-
pliance and increasing the efficacy of therapy.
Themain strengths of our score are that it is simple to use in
clinical practice, requires no additional costs, can easily be
obtained without risk of biases, and gives an early and reliable
prediction of treatment effectiveness. The main limitation of
this study is its retrospective design, while its strengths are a
large sample size and multicentric enrolment of patients in a
field-practice setting.
In conclusion, we validated a simple scoring system useful
to predict outcomes in HCC patients treated with sorafenib.
This score is simple to calculate and may be an ideal tool to be
implemented in daily clinical practice. Using the OTE score,
the clinicianmay predict the effectiveness of sorafenib therapy
and refine the therapeutic strategy. For example, patients with
positive predictors should be encouraged to continue sorafe-
nib and, if indicated, combined locoregional treatments can be
used to increase the tumor response and OS. Conversely, in
patients with an OTE score of 0 (about one-third of our pop-
ulation), sorafenib treatment has a very high chance of being
inefficacious. In these patients discontinuation of sorafenib
should be considered, and the second-line drug regorafenib
(Stivarga®, Bayer Health Care, Leverkusen, Germany) or ex-
perimental anti-cancer treatments should be offered.
Prospective studies are needed to confirm the prognostic abil-
ity of our OTE score and its utility in refining treatment
strategies.
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